Patent · US Active

Pan-KIT kinase inhibitor having quinoline structure and application thereof

US12404244B2 · kind B2 · utility

0Cited by

1References

8Claims

0Family size

Assignee

Tarapeutics Science Inc. · CN

Inventors

Jing Liu · San Diego, US
Qingsong LIU · Daguantang, CN
Yun Wu · Wuxi, CN
Beilei Wang · Meekrap-oord, CN
ZiPing Q · Daguantang, CN
Fengming ZOU · Daguantang, CN
Qingwang LIU · Daguantang, CN
Wenchao Wang · Beijing, CN
Cheng-Yu Chen · Longbeilingcun, CN
Junjie Wang · Beijing, CN
Li-Ting Wang · Meekrap-oord, CN

Key dates

Filing date	Dec 20, 2018
Grant date	Sep 2, 2025
Priority date	—
Expiry date	Oct 9, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. The compound and composition above can inhibit wild-type KIT and/or mutant KIT tyrosine kinase activity and treat, prevent, or alleviate diseases, disorders, or conditions associated with wild-type KIT and/or mutant KIT kinase activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.